Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.49 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | DHODH | Q02127 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 4/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.46 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29786964 | 0.87 | CSNK2A1 (0.55) | TNFMAPKAPK2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL20338809 | 0.87 | CSNK2A1 (0.55) | TNFMAPKAPK2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL29787033 | 0.86 | TNF (0.57) | TNFPOLBDHODHMEN1RAB9A | |
| SCHEMBL20338691 | 0.86 | TNF (0.57) | TNFPOLBDHODHMEN1RAB9A | |
| SCHEMBL29786941 | 0.84 | P4HTM (0.48) | TNFCSNK2A1CSNK2A2CSNK2BDHODH | |
| SCHEMBL20356763 | 0.84 | P4HTM (0.48) | TNFCSNK2A1CSNK2A2CSNK2BDHODH | |
| SCHEMBL29786991 | 0.84 | HCAR3 (0.47) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL20338847 | 0.84 | HCAR3 (0.47) | CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL29787022 | 0.83 | TNF (0.44) | TNFCSNK2A1CSNK2A2CSNK2BDHODH | |
| SCHEMBL20338676 | 0.83 | TNF (0.44) | TNFCSNK2A1CSNK2A2CSNK2BDHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11440898-B2 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | MINORYX THERAPEUTICS S.L. (ES) | 2022-09-13 | — | — | US | disclosed |
| CN-110494432-B | Isoquinoline compounds, methods of preparation thereof and therapeutic use thereof in disorders associated with altered beta-galactosidase activity | 米尼奥尔克斯治疗有限公司 | 2022-08-12 | — | — | CN | disclosed |
| EP-3562821-B9 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2021-05-26 | — | — | EP | disclosed |
| EP-3562821-B9 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2021-05-26 | — | — | EP | disclosed |
| EP-3562821-B1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2020-12-02 | — | — | EP | disclosed |
| EP-3562821-B1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S L (ES) | 2020-12-02 | — | — | EP | disclosed |
| US-20200071294-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S.L. (ES) | 2020-03-05 | — | — | US | disclosed |
| US-20200071294-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S.L. (ES) | 2020-03-05 | — | — | US | disclosed |
| EP-3562821-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | Minoryx Therapeutics S.L. (ES) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018122746-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S.L. (ES) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018122746-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | MINORYX THERAPEUTICS S.L. (ES) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440898-B2 | Isoquinoline compounds, methods for their preparation, and therapeutic uses thereof in conditions associated with the alteration of the activity of beta galactosidase | GLB1, GBA1, GALC | TNF 2513/4885MAPKAPK2 4363/4885CSNK2A1 701/4885 |
| US-20200071294-A1 | ISOQUINOLINE COMPOUNDS, METHODS FOR THEIR PREPARATION, AND THERAPEUTIC USES THEREOF IN CONDITIONS ASSOCIATED WITH THE ALTERATION OF THE ACTIVITY OF BETA GALACTOSIDASE | GLB1, GBA1, GALC | TNF 2513/4885MAPKAPK2 4363/4885CSNK2A1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.